GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » ROCE %

AP Biosciences (ROCO:6945) ROCE % : -45.56% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AP Biosciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -45.56%.


AP Biosciences ROCE % Historical Data

The historical data trend for AP Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences ROCE % Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROCE %
7.00 -66.82 -34.83 -34.52

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial - -58.19 -22.96 -21.68 -45.56

AP Biosciences ROCE % Calculation

AP Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-338.092/( ( (1103.179 - 4.519) + (890.756 - 30.875) )/ 2 )
=-338.092/( (1098.66+859.881)/ 2 )
=-338.092/979.2705
=-34.52 %

AP Biosciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-440.626/( ( (1099.078 - 24.889) + (890.756 - 30.875) )/ 2 )
=-440.626/( ( 1074.189 + 859.881 )/ 2 )
=-440.626/967.035
=-45.56 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AP Biosciences  (ROCO:6945) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


AP Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of AP Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


AP Biosciences (ROCO:6945) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences (ROCO:6945) Headlines

No Headlines